36results about How to "Prolong the time of action in the body" patented technology

The invention discloses a suspension preparation of temperature change painless nano sulfadiazine metallic compound hyaluronic acid. The formula comprises a sulfadiazine metallic compound, a hyaluronic acid substance, an analgetic, a dispersing agent aid, a suspension aid and water, wherein the sulfadiazine metallic compound comprises sulfadiazine silver and sulfadiazine zinc; the hyaluronic acid substance is sourced from biological fermentation and animal tissue extraction and the like and can be hyaluronic acid or hyaluronate or crosslinked hyaluronic acid or crosslinked hyaluronate; the analgetic comprises ropivacaine, bupivacaine, levobupivacaine, lidocaine and other local anesthetics or combination of the local anesthetics; the dispersing agent aid comprises chlorhexidine, Tween series, oleic acid or sodium oleate; the suspension aid can comprise glycerinum, celluloses, poloxamer series and hyaluronic acid substances. The suspension preparation is mainly used for burn, scald or the surface of a wound caused by explosion or anabrosis, has the main clinical characteristics that pain is rapidly relieved, the surface of the wound is subjected to rapid film formation and rapid healing of the wound is promoted, and the conventional main administration modes refer to spraying, smearing and coating.

Belonging to the field of tumor gene therapy, the present invention provides an anti-tumor RNA interference plasmid-lipidosome-heparin complex targeting the human FAK and FLK1 genes. The RNA interference expression vector can express a RNA interference sequence aimed at a target site shown by SEQ ID NO:1 on the FAK gene and a RNA interference sequence aimed at a target site shown by SEQ ID NO:2 on the FLK1 gene in the body. The FAK and PLK1 dual-gene RNA interference plasmid prepared by the present invention can effectively inhibit the growth of lung cancer cells and induce the lung cancer cells to be apoptosed. A tumor inhibition experiment conducted in the body also indicates that the FAK and PLK1 dual-gene RNA interference plasmid-lipidosome-heparin complex can notably inhibit the growth of manifold tumors and prolong the lifetime of tumor-bearing mice. The product of the anti-tumor RNA interference plasmid-lipidosome-heparin complex has obvious efficacy and can reduce dosage and improve the life quality of patients, thus having a good application prospect.

The invention belongs to the preparation and application technical field of the liposome and specifically discloses a preparation method and application of targeted multi-function double drug-loading liposome. The raw material for the targeted multi-function double drug-loading liposome comprises the basic film material phospholipid, polyethylene glycol modified phospholipid capable of prolonging the half-life period of the liposome medicine blood, phospholipid capable of having fluorescence imaging, phospholipid having targeted function, lipid-soluble drug and water-soluble drug treating the tumor and contrast agent capable of strengthening nuclear magnetism imaging signal. The medicine can solve the clinic use defect of the medicine with poor water solubility through the package of the phospholipid, the method of administration of the conventional medicine is changed by combining with the water-soluble drug, the targeting action is achieved for the tumor tissue for effectively restraining the tumor growth, reducing the production of the side reaction; the medicine action effect and the tumor change condition can be observed in real time through MRI and great clinical application value is achieved.

The invention relates to indolone compounds shown as a general formula (a) or derivatives thereof and applications thereof. According to the invention, indolone compounds are substituted with deuterium to obtain deuterium-enriched indolone compounds; the indolone compounds can simultaneously act on the following three key receptor families involved in angiogenesis process: vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR), so as to inhibit angiogenesis and achieve the effect of treating cancers. The deuterated indolone compounds or the derivatives thereof have the advantage of high efficiency when used asdrugs. The general formula (a) is as shown in the specification.

The invention discloses an exenatide modified compound, a use of the exenatide modified compound in preparation of a medicine which serves as a GLP-1 receptor stimulant, a use of the exenatide modified compound in preparation of medicines used for preventing and/or curing diseases and/or symptoms relevant to low GLP-1 receptor activity, a use of the exenatide modified compound in preparation of medicines used for diseases and/or symptoms relevant to carbohydrate metabolism, a use of the exenatide modified compound in preparation of medicines used for diabetes, a use of the exenatide modified compound in preparation of medicines used for fatty liver, and a use of the exenatide modified compound in preparation of medicines used for weight losing.

The invention discloses a carboxylated mPEG (polyethylene glycol methyl ether)-ICA (icariin) nanoparticle, a preparation method and an application. The nanoparticle comprises ICA as a hydrophobic endand carboxylated mPEG as a hydrophilic end. In an aqueous solution, the mPEG part is linked to form a hydrophilic shell, ICA is used as a hydrophobic core, and a nano-scale mPEG-ICA polymer microsphere of a spherical core-shell structure is formed spontaneously. According to the carboxylated mPEG-ICA nanoparticle, the water solubility of ICA can be increased, the acting time of medicines in vivo can be prolonged, and the slow release effect can be enhanced.

The invention provides a trimetazidine hydrochloride bi-layer osmotic pump controlled release tablet and a preparation method thereof. The osmotic pump controlled release tablet is formed by a drug-containing layer, a booster layer and a coating film, wherein the drug-containing layer comprises the following components in percentage by weight: 10-50% of trimetazidine hydrochloride, 30-80% of suspension agent and the balance of other auxiliary materials; the booster layer comprises the following components in percentage by weight: 20-90% of swelling agent, 5-70% of osmotic active substance and 0.5-5% of lubricating agent; the semipermeable coating film comprises 10-20g of semipermeable high polymer material and 1-5g of water-soluble pore-forming agent every 100 tablets. The trimetazidine hydrochloride bi-layer osmotic pump controlled release tablet can realizes constant release of drug in the body of a patient without being affected by pH value of a medium environment, enzyme, gastrointestinal motility and food, and is capable of maintaining the stability of plasma concentration of drug, reducing toxic and side effects of drug, decreasing dosing frequency and improving compliance of the patient.

The invention belongs to the field of biotechnological genetic engineering, and mainly relates to construction of an expression vector of anti-microbial fusion proteins and application thereof. The construction aims at the problems of narrow antimicrobial spectrum and bad antimicrobial effects of antimicrobial peptides in the prior art, the anti-microbial fusion proteins utilize codon preference,a fusion protein gene is designed and synthesized, a recombined vector is constructed, and after the vector is introduced into host cells, and the fusion proteins containing an antimicrobial protein segment rBPI21 and an antimicrobial peptide LL-37 are obtained. The fusion proteins have large molecular weight, can prolong internal action time of fusion proteins, have wider antimicrobial spectrum and largely enhanced sterilization effects, can be widely applied to the anti-microbial, anti-endotoxin and other technology fields, and provide a new selection for biological sterilization medicaments.

A composition containing hyalurates is provided. The composition comprises a double-gel system consisting of crosslinked hyalurate gel and non-crosslinked hyalurate gel. The pH of the double-gel system is 6.0-8.0, the average particle size is 100-300 [mu]m, the kinematic viscosity is 10-80 mm<2>/s, and the extruding force is 5-30 N. The invention also provides a preparation method of the composition containing hyalurates. The method includes preparing the crosslinked hyalurate gel by utilizing a first hyaluronic acid or hyalurate; preparing the non-crosslinked hyalurate gel by utilizing a second hyaluronic acid or hyalurate; mixing the crosslinked hyalurate gel and the non-crosslinked hyalurate gel; and performing high-temperature treatment to obtain the double-gel system. The composition,compared with traditional hyaluronic acid water-gloss products, has enhanced resistance to hyaluronidase, longer action time in vivo, low gel viscosity, a high slip degree and enhanced fluidity, is easier to extrude and operate during clinical use, and can reduce the occurrence of side reactions such as skin hills and redness.

The invention relates to an albendazole chitosan microsphere composition and a preparation method thereof. The albendazole chitosan microsphere composition consists of albendazole and chitosan. The preparation method comprises the following steps of: dissolving albendazole and chitosan in a dilute acetic acid solution to form an aqueous phase, and dissolving a surfactant in oil to form an oil phase, wherein the volume ratio of the aqueous phase to the oil phase is (1:2)-(1:8); injecting the aqueous phase into the oil phase and stirring to obtain an emulsion; adding a crosslinking curing agent into the emulsion while stirring; after the crosslinking curing of microspheres is finished, performing centrifugal separation; washing with petroleum ether; and drying to obtain the albendazole chitosan microspheres. The albendazole chitosan microspheres provided by the invention have the characteristics of narrow particle size distribution, high encapsulation efficiency and simple preparation method; and compared with albendazole tablets, the albendazole chitosan microsphere composition has the advantages that the bioavailability is obviously improved to reach about 500% of the bioavailability of the albendazole tablets, the action time of the medicine can be prolonged, and the in-vivo medicine release time is increased to 48 hours.

The invention discloses a medicinal composition containing lentinan. The medicinal composition comprises, by weight, 0.5-5% of lentinan, 1-10% of yeast glucan, 2-10% of levamisole hydrochloride, 5-30% of licorice root extract, and the balance of anhydrous glucose. The invention also discloses a preparation method of the medicinal composition, and a use of the composition in enhancement of the immunity of animals. The medicinal composition which is processed through an ultrafine crushing technology has a high medicine absorption rate, substantially promotes the growth of animal immune organs and enhances the immunity of animal bodies; the medicinal composition has a substantial curative effect on viral disease induced immunosuppression and poor immunity, and substantially reduces the mortality of pathogenetic animals; the medicinal composition substantially increases the antibody tilter of vaccine immunized serum of the animals in order to substantially enhance the vaccine immunization effect; and the composition has the advantages of simple production steps, convenience in clinic use, and convenience in colony administration.

The invention relates to a pharmaceutical composition sustained-release implant containing caspofungin acetate and a preparation method thereof. The pharmaceutical composition sustained-release implant is characterized in that the active ingredient of the medicine is echinocandins antifungal drug caspofungin acetate. In addition, the sustained-release implant also comprises polyene and triazole antifungal drugs with a synergistic effect with the caspofungin. The active ingredient of the medicine is coated in a high polymer material carrier with biodegradability and biocompatibility according to a certain ratio. The active ingredient is prepared into sustained-release microspheres to be directly pressed into tablets of a certain shape, and the tablets are used for implant, so that a long-acting sustained-release effect is achieved. The sustained-release period of the sustained-release implant lasts for several days or several months, the drug administration frequency is obviously reduced, the bioavailability is improved, the toxic and side effects are reduced, and thus the pharmaceutical composition sustained-release implant containing caspofungin acetate is beneficial for clinical treatment.

The invention discloses an insulin modification method. Chemical coupling is adopted to combine a water-soluble polymer and the insulin through covalent bonding, wherein firstly the insulin is dissolved in a solvent, triethylamine and di-tert-butyl dicarbonate are added and stirred for a reaction, and a product A is obtained through freeze-drying and separation; then, a water-soluble polymer monomer is dissolved in a solvent, an RAFT reagent and an initiator are added for a reaction to obtain a product B; the product A and the product B are weighed, a solvent triethylamine is added, a productC is obtained through dialysis and freeze-drying, the product C is dissolved in water, trifluoroacetic acid is added for a reaction, and a coupled product D of the polymer and the insulin is obtainedthrough dialysis and freeze-drying. The chemically modified insulin is protected from degradation and inactivation by enzymes and the acid environment in the gastrointestinal environment through the water-soluble polymer, so that the degradation of the digestive enzymes of the gastrointestinal tract is effectively inhibited, and the product property is stable.

The present invention discloses a compound hericium dry suspension preparation. It is made up by using 600 g of hericium sporophore, 100 g of sucralfate, 50 g of magnesium trisilicate, 40 g of bismuth subnitrate, 5-15 g of polyvinylpyrrole, 50-160 g of lactose, 120-200 g of hydroxypropyl methyl cellulose, 2-6 g of Tween-80, 10-50 g of aromadenadrin powder and 3-15 g of sodium glutamate through the processes of pulverizing, granulating and filling. It has good therapeutic effect for curing ulcer of digestive tract.